Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 2 of 2 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 2 of 2
The authors describe the importance of a rapid and an abbreviated screening strategy in initial solvent screening. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 6


Figure 7: Solubility curves of Form A phenylbutazone in 17 solvents.
The solubility curves of Form III carbamazepine in 13 single good solvents, Form A cimetidine in five single good solvents, and Form A phenylbutazone in 17 single good solvents are shown in Figures 5, 6, and 7, respectively. The solubility of all three APIs in different solvents increased with temperature. The enthalpy of dissolution (ΔHd) and the entropy of dissolution (ΔSd) of an API in a particular good solvent could be approximated from the slope and the y-intercept of a straight line, respectively, when the solubility curve of the API in that particular good solvent was replotted in the form of the van 't Hoff equation (16).


Figure 8
Solids characterizations. All API solids generated from the saturated solutions of their corresponding good solvents by temperature cooling were isolated and analyzed with optical microscopy, DSC, thermogravimetric analysis (TGA), and FTIR. Optical micrographs of carbamazepine, cimetidine, and phenylbutazone solids are illustrated in Figures 8, 9, and 10, respectively. The crystal habits, the aspect ratios, the polymorphism, and the crystallinity of carbamazepine, cimetidine, and phenylbutazone solids grown from the 13 good solvents are summarized in Table IV.


Figure 9
Most of the carbamazepine solids exhibited the typical DSC thermograms for Form III and Form I crystals, respectively. Unlike Form III carbamazepine crystals, Form I crystals showed no transformation and only one sharp melting endotherm at 190 C (17). A carbamazepine acetone solvate produced in acetone agreed with this observation (18). The TGA scan (see Figure 11) further showed that the carbamazepine acetone solvate had a 1:1 stoichiometric ratio and the DSC curve (see Figure 11) demonstrated the removal of acetone from the solvate at 50–88 C and a phase change of the material to Form I with a melting endotherm at 190 C (17, 19).


Table IV: Crystal habits, aspect ratios, polymorphism, and crystallinity of solids of carbamazepine, cimetidine, and phenylbutazone generated from their corresponding good solvents.
In contrast with the previous observations that solvents with low dielectric constants yielded Form I crystals and those with high dielectric constants yielded Form III crystals, the authors obtained Form I needles not only from solvents such as chloroform and 1,4-dioxane with low dielectric constants, but also from acetonitrile with a high dielectric constant (see Figures 8c, 8g, and 8j) (1, 18, 20, 21). Form III prisms were also harvested from a solvent such as isopropyl alcohol with a low dielectric constant when enough aging time was given for the transformation of Form I to Form III according to Ostwald's Rule of Stages (see Figure 8i). The rest of the good solvents generated the thermodynamically stable Form III prisms (see Figures 8a, 8b, 8d, 8e, 8f, 8h, 8k, 8l, and 8m) (1, 20, 21). Isopropyl alcohol tended to give a mixture of needled and prismatic carbamazepine solids (see Figure 8i). The interplay between thermodynamics and kinetics made concomitant crystallization possible (22). The DSC curves of the physically isolated needles and prisms by a pair of tweezers were resolved to Form I (see Figure 1) and Form III crystals, respectively.


Figure 10
Apparently, the needle or prism crystal habit of carbamazepine was affected only by polymorphism and not by microscopic properties such as the Hansen parameters and the dielectric constants of the solvents. The dominant factor that influenced the crystallization outcomes could have been the degree of supersaturation imposed by temperature cooling, which placed the crystallization under either kinetic or thermodynamic control (22). This inference was supported by the feasibility of a one-solvent polymorph screen of carbamazepine and the appearance of the metastable Form I carbamazepine from a high degree of supersaturation, either by a sudden drop of the solubility through the introduction of an antisolvent or by cooling the system with a relatively steep solubility curve such as chloroform and acetonitrile (see Figure 5) (11). The drive for structures that could be formed more quickly than others might override the drive for settling with structures of the maximum decrease in energy. However, this speed seldom affected the crystallinity, as was seen by the relatively high percent crystallinity of Form I carbamazepine crystals.


Figure 11: Differential scanning calorimetry and thermogravimetric analysis scans of 1:1 carbamazepine acetone solvate made from acetone.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here